Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors / Wei-Hua Shao, Lei-Yun Wang, Ji-Ye Yin
Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Current pharmacogenomics and personalized medicine - 16(2018), 2, Seite 108- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shao, Wei-Hua [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009084401 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009084401 | ||
| 003 | DE-627 | ||
| 005 | 20231129095713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2018 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009084401 | ||
| 035 | |a (KFL)prod_DARH_.C773B8DB1F9BC3F4010CE214444269EC7A996538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Shao, Wei-Hua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors |c Wei-Hua Shao, Lei-Yun Wang, Ji-Ye Yin |
| 264 | 1 | |c 2018 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors | ||
| 700 | 1 | |a Wang, Lei-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Ji-Ye |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacogenomics and personalized medicine |d Sharjah : Bentham, 2008 |g 16(2018), 2, Seite 108- |h Online-Ressource |w (DE-627)KFL000006556 |w (DE-600)2424232-9 |w (DE-576)30683636X |x 1875-6913 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:2 |g pages:108- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1875-6921&volume=16&issue=2&spage=108 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 2 |h 108- | ||